Literature DB >> 26614906

Hairy cell leukemia: Past, present and future.

Bartlomiej M Getta1, Jae H Park2, Martin S Tallman3.   

Abstract

This brief review highlights the sequence of therapeutic milestones and advances in our understanding of the biology of hairy cell leukemia (HCL) with a focus on recent molecular findings and how these may be applied to improve disease outcomes in the future. Targeted therapy is discussed in the context of the recently identified BRAF mutation and other genetic findings.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  BRAF; Hairy cell leukemia; Vemurafenib

Mesh：

Substances：

Year:  2015        PMID： 26614906      PMCID： PMC5008915          DOI： 10.1016/j.beha.2015.10.015

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  27 in total

1.  Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.

Authors:  Justin E Sausville; Rita G Salloum; Lynn Sorbara; Douglas W Kingma; Mark Raffeld; Robert J Kreitman; Paula D Imus; David Venzon; Maryalice Stetler-Stevenson
Journal:  Am J Clin Pathol       Date:  2003-02       Impact factor: 2.493

2.  Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

Authors:  Liqiang Xi; Evgeny Arons; Winnifred Navarro; Katherine R Calvo; Maryalice Stetler-Stevenson; Mark Raffeld; Robert J Kreitman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

3.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

4.  Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.

Authors:  Francesco Forconi; Elisa Sozzi; Emanuele Cencini; Francesco Zaja; Tamara Intermesoli; Caterina Stelitano; Luigi Rigacci; Filippo Gherlinzoni; Renato Cantaffa; Anna Baraldi; Andrea Gallamini; Alfonso Zaccaria; Alessandro Pulsoni; Marco Gobbi; Maristella Tassi; Donatella Raspadori; Lorenzo Leoncini; Andrea Rinaldi; Elena Sabattini; Francesco Bertoni; Stefano A Pileri; Francesco Lauria
Journal:  Blood       Date:  2009-08-10       Impact factor: 22.113

5.  BRAF mutations in hairy-cell leukemia.

Authors:  Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  N Engl J Med       Date:  2011-06-11       Impact factor: 91.245

6.  Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.

Authors:  Monica Else; Claire E Dearden; Estella Matutes; Francesco Forconi; Francesco Lauria; Humayun Ahmad; Susan Kelly; Anandika Liyanage; Vijitha Ratnayake; Jagadeesan Shankari; Ioana Whalley; Daniel Catovsky
Journal:  Leuk Lymphoma       Date:  2011-04-19

7.  Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).

Authors:  D H Robbins; I Margulies; M Stetler-Stevenson; R J Kreitman
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

8.  Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

Authors:  Robert J Kreitman; Martin S Tallman; Tadeusz Robak; Steven Coutre; Wyndham H Wilson; Maryalice Stetler-Stevenson; David J Fitzgerald; Robert Lechleider; Ira Pastan
Journal:  J Clin Oncol       Date:  2012-02-21       Impact factor: 44.544

9.  Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias.

Authors:  Sebastian Tschernitz; Lucia Flossbach; Margrit Bonengel; Sabine Roth; Andreas Rosenwald; Eva Geissinger
Journal:  Br J Haematol       Date:  2014-01-16       Impact factor: 6.998

10.  The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.

Authors:  Mariela Sivina; Robert J Kreitman; Evgeny Arons; Farhad Ravandi; Jan A Burger
Journal:  Br J Haematol       Date:  2014-04-02       Impact factor: 6.998
View more
  3 in total

1.  The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.

Authors:  Francesca Guerrini; Matteo Paolicchi; Francesco Ghio; Elena Ciabatti; Susanna Grassi; Serena Salehzadeh; Giacomo Ercolano; Maria R Metelli; Marzia Del Re; Lorenzo Iovino; Iacopo Petrini; Giovanni Carulli; Nadia Cecconi; Martina Rousseau; Giulia Cervetti; Sara Galimberti
Journal:  Front Pharmacol       Date:  2016-10-13       Impact factor: 5.810

2.  Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Authors:  Robert J Kreitman; Claire Dearden; Pier Luigi Zinzani; Julio Delgado; Lionel Karlin; Tadeusz Robak; Douglas E Gladstone; Philipp le Coutre; Sascha Dietrich; Mirjana Gotic; Loree Larratt; Fritz Offner; Gary Schiller; Ronan Swords; Larry Bacon; Monica Bocchia; Krimo Bouabdallah; Dimitri A Breems; Agostino Cortelezzi; Shira Dinner; Michael Doubek; Bjorn Tore Gjertsen; Marco Gobbi; Andrzej Hellmann; Stephane Lepretre; Frederic Maloisel; Farhad Ravandi; Philippe Rousselot; Mathias Rummel; Tanya Siddiqi; Tamar Tadmor; Xavier Troussard; Cecilia Arana Yi; Giuseppe Saglio; Gail J Roboz; Kemal Balic; Nathan Standifer; Peng He; Shannon Marshall; Wyndham Wilson; Ira Pastan; Nai-Shun Yao; Francis Giles
Journal:  Leukemia       Date:  2018-07-20       Impact factor: 11.528

Review 3.  Moxetumomab Pasudotox: First Global Approval.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.